Open Access

Angiotensin II in vasodilatory shock: lights and shadows

Critical Care201721:277

https://doi.org/10.1186/s13054-017-1869-9

Received: 17 October 2017

Accepted: 23 October 2017

Published: 14 November 2017

Data from the literature show lights and shadows about the use of angiotensin II (Ang II), for instance as an alternative vasopressor in patients with vasodilatory shock that requires high doses of catecholamines. Recently, an international randomized controlled trial (ATHOS-3) [1] has shown that Ang II can induce a significant increase in mean arterial pressure (MAP) if compared to placebo. Moreover, during the first 48 hours from the randomization, doses of the vasopressors (norepinephrine (NE) and vasopressin) were significantly reduced in the Ang II group but not in the placebo group. Interestingly, no difference in adverse effects was remarkable between the two groups.

However, some important issues need to be clarified before any definitive conclusion about Ang II in vasodilatory shock. Firstly, we do not know exactly the timing for Ang II initiation: is it better to add Ang II only when NE doses jump to 0.2 μg/kg/min or when NE requirements rapidly increase (e.g., 0.5 μg/kg every hour)? Secondly, Ang II could be administered to specific patients. In previous studies, some patients were extremely sensitive to Ang II infusion (e.g., medication with ACE inhibitors; sartans or beta-blockers) [2, 3]. Furthermore, cirrhotic patients usually show a reduced angiotensinogen synthesis with secondary low circulating levels of Ang II [4]. In this perspective, could we hypothesize that an early infusion of Ang II has a positive effect on these patients? Thirdly, the safety profile of Ang II has never been tested in patients with vasodilatory shock and concurrent myocardial dysfunction. According to the case of the nonselective nitric oxide synthase inhibitor [5], Ang II could reduce the cardiac output due to its preferential vasoconstrictive action and provide some detrimental effects for those patients with myocardial dysfunction. Finally, Ang II significantly increased the heart rate (HR) in the ATHOS-3 trial. However, Ang II should not have a positive chronotropic effect and the authors did not manage to provide us with a reason for this phenomenon. We can only hypothesize that the increased HR is related to a relative hypovolemia. However, also in this case no clear information about the volemic status was found in the ATHOS-3 trial (e.g., total fluid administration or total fluid balance; cardiac index measurements missed in 56% of cases).

In conclusion, Ang II is doubtless a promising vasopressor but some questions still need to be answered before any definitive conclusion in the field.

Abbreviations

Ang II: 

Angiotensin II

HR: 

Heart rate

MAP: 

Mean arterial pressure

NE: 

Norepinephrine

Declarations

Acknowledgements

Not applicable.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Authors’ contributions

EA, SA, and YS wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Intermediate Care Unit, Guglielmo da Saliceto Hospital
(2)
Department of Anesthesia and Intensive Care, Uniklinikum

References

  1. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419–30.View ArticlePubMedGoogle Scholar
  2. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18:534.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Wray GM, Coakley JH. Severe septic shock unresponsive to noradrenaline. Lancet. 1995;46:1604.View ArticleGoogle Scholar
  4. Antonucci E, Gleeson PJ, Annoni F, Agosta S, Orlando S, Taccone FS. Angiotensin II in refractory septic shock. Shock. 2017;47:560–6.View ArticlePubMedGoogle Scholar
  5. López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21–30.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement